Regeneronβs Strategic Bet: Acquires 23andMe’s Assets to Supercharge Genetic Drug Research
Regeneron acquires key assets of 23andMe for $256M amid bankruptcy, aiming to boost genetic drug research with access to 15M+ DNA profiles.
Tag Regeneron
Regeneron acquires key assets of 23andMe for $256M amid bankruptcy, aiming to boost genetic drug research with access to 15M+ DNA profiles.